Triomed Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Triomed General Information

Description

Manufacurer of portable dialysis system intended to improve the lives of end-stage renal disease patients. The company offers a modular dialysis system that addresses the key reasons patients leave peritoneal dialysis and adapts to treat the patients in the different stages of their disease progression, enabling patients to get improved treatment at reduced costs.

Contact Information

Website
www.triomed.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Ideon Science Park
  • Scheelevägen 20
  • 223 63 Lund
  • Sweden
+46 046-460
Primary Industry
Therapeutic Devices
Vertical(s)
Corporate Office
  • Ideon Science Park
  • Scheelevägen 20
  • 223 63 Lund
  • Sweden
+46 046-460

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Triomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private Completed Generating Revenue
2. Later Stage VC Completed Generating Revenue
1. Later Stage VC 26-Jan-2012 Completed Generating Revenue
To view Triomed’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Triomed Patents

Triomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3651828-A1 Dialysis device comprising an evaporator/condenser device Inactive 14-Jul-2017
US-20200164129-A1 Dialysis device comprising an evaporator/condenser device Inactive 14-Jul-2017
EP-3651828-A4 Dialysis device comprising an evaporator/condenser device Inactive 14-Jul-2017
US-10946130-B2 Apparatus for performing peritoneal ultrafiltration Active 27-Aug-2015
ES-2839174-T3 Apparatus for peritoneal ultrafiltration Active 27-Aug-2015 A61M1/28
To view Triomed’s complete patent history, request access »

Triomed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Triomed Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Almi Invest Venture Capital Minority
Frankenius Equity Family Office Minority
KMG Capital Partners Venture Capital Minority
To view Triomed’s complete investors history, request access »

Triomed FAQs

  • When was Triomed founded?

    Triomed was founded in 2000.

  • Where is Triomed headquartered?

    Triomed is headquartered in Lund, Sweden.

  • What is the size of Triomed?

    Triomed has 31 total employees.

  • What industry is Triomed in?

    Triomed’s primary industry is Therapeutic Devices.

  • Is Triomed a private or public company?

    Triomed is a Private company.

  • What is Triomed’s current revenue?

    The current revenue for Triomed is .

  • Who are Triomed’s investors?

    Almi Invest, Frankenius Equity, and KMG Capital Partners have invested in Triomed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »